Positive impactCompany
Dr Reddy’s expands pact with Gilead for investigational HIV prevention drug
BusinessLine 2 hrs ago·17 Sept 2026, 7:36 am
Dr Reddy's and Gilead have broadened their collaboration to include lenacapavir, an investigational long‑acting HIV prevention drug that is already approved in the US and Europe and recommended by the WHO.
The extension means Dr Reddy's will help with manufacturing, regulatory filing and commercial rollout in India and possibly other emerging markets, giving the company a foothold in a high‑growth preventive therapy segment and diversifying its pipeline beyond its existing products.
Investors will be watching how quickly the drug moves through Indian regulatory approval, the pricing strategy, and any data from ongoing studies that could affect market uptake, as well as competition from other long‑acting HIV preventives.
Excerpt from BusinessLine
Dr. Reddy’s Laboratories has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences for investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreement builds on Dr. Reddy’s existing voluntary licensing arrangement with Gilead, signed…Read the original at BusinessLine
Key takeaways
- Category: Company.
- AI reads the tone as positive (potentially bullish) for the stock.
- Assessed as a significant, market-relevant update.
Why it matters
A meaningful update worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
